Replimune Group Inc. Chief Strategy Officer Sushil Patel filed a Form 144 notice of proposed sale of 15,331 shares of common stock, with an approximate sale date of November 20, 2026, executed through J.P. Morgan Securities LLC under a Rule 10b5-1 plan adopted on August 21, 2026.
Key Highlights
- Filer and role: Sushil Patel, Chief Strategy Officer of Replimune Group Inc., is the person for whose account the securities are to be sold.
- Shares proposed for sale: 15,331 shares of common stock, with an aggregate market value of $288,223 as stated in the filing.
- Source of shares: The shares were acquired via RSU vest from the issuer on May 15, 2023, with 15,331 units acquired on that date.
- Shares outstanding: The filing lists 94,800,404 shares of common stock outstanding.
- Broker: J.P. Morgan Securities LLC, 270 Park Avenue, 10th Floor, New York, NY 10017, is named as the executing broker.
- 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of August 21, 2026.
- Prior sales: The filing reports nothing to report under securities sold during the past 3 months.
Replimune Group Chief Strategy Officer Files Proposed Stock Sale Notice
According to the Form 144 filed with the U.S. Securities and Exchange Commission, Sushil Patel, who serves as Chief Strategy Officer of Replimune Group Inc. (NASDAQ:REPL), has provided notice of a proposed sale of 15,331 shares of the company's common stock. The filing lists an approximate sale date of November 20, 2026, and identifies J.P. Morgan Securities LLC as the broker acting as agent and attorney-in-fact for Patel. The aggregate market value of the shares proposed to be sold is stated in the filing as $288,223.
The filing discloses that the 15,331 shares were acquired through an RSU vest transaction from the issuer on May 15, 2023, with the date of payment also listed as May 15, 2023, and the nature of payment noted as "NA." The filing reports no other securities of Replimune sold by Patel during the three months preceding the notice date. The issuer's address is listed as 500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts 01801, and the SEC file number is 001-38596.
The notice indicates that the proposed sale is intended to be made in reliance on Rule 144 under the Securities Act of 1933, and that a Rule 10b5-1 trading plan was adopted on August 21, 2026. By signing the form, the filer represents, as of the plan adoption date, that he did not possess material adverse information regarding Replimune's current and prospective operations that had not been publicly disclosed, according to the filing's standard attestation language.
What Was Disclosed
Replimune Group's Chief Strategy Officer Sushil Patel filed a Form 144 notice proposing the sale of 15,331 common shares with an aggregate market value of $288,223, acquired via RSU vest on May 15, 2023, with a sale date of November 20, 2026, under a 10b5-1 plan.




Please wait processing your request...